SIWA CEO and Chief Scientific Officer, Lewis Gruber, was featured in a recent interview with Supertrends where he discussed how SIWA 318H targets cancerous, senescent, and virally infected cells. Read the full interview here: https://www.supertrends.com/senolytics-showcase-link-between-life-extension-and-therapeutics/
"While SIWA’s focus remains on developing a powerful therapeutic for aggressive cancers, the Covid-19 pandemic presented us with an opportunity to explore how 318H could also be used to treat infectious diseases." In this interview, our CEO and Chief Scientific Officer, Lewis Gruber, discusses the results of our recent preclinical tests, which confirmed 318H shows promise to become both a comprehensive cancer therapy and a broad-spectrum antiviral drug. Read the full interview here: https://startup.info/lewis-gruber-siwa-therapeutics/
We are pleased to announce that Lewis Gruber was recently named to the Aging Analytics Agency’s list of 1000 Longevity Leaders recognized in the research and academia sector for his work with SIWA Therapeutics. Aging Analytics is the longest-running and most comprehensive interactive platform of longevity professionals. The agency profiles public and private-sector influencers whose work in business, science, policy, philanthropy, or thought-leadership is instrumental in the longevity landscape.
SIWA Therapeutics is pleased to announce our participation in BIO Digital 2020, a virtual gathering of the global biotech industry. BIO is the world's largest trade association, which represents biotechnology companies, academic institutions, and other organizations on the forefront of innovation. This year, the BIO International Convention will transition into an entirely virtual event, providing even closer access to key partners via the BIO One-on-One Partnering. We look forward to our discussions at this year’s unique platform on June 8-12! If attending, please reach out to us firstname.lastname@example.org
SIWA Therapeutics is excited to announce that we are doing our part in the global fight against COVID-19. Our humanized monoclonal antibody targets cells with an abnormally high level of glycolysis (known as the Warburg effect in cancer) and oxidative stress. This category includes, among other things, virally infected cells, including those infected by COVID-19. Read more below: http://biospace.com/article/chicago-biotech-company-testing-its-monoclonal-antibody-to-treat-covid-19/
Our founder and Chief Scientific Officer, Lewis Gruber recently spoke with Jim Dallke, Senior Editor of AmericanInno and contributor to American City Business Journals about SIWA Therapeutic’s groundbreaking work to defeat aging and age-related diseases. Read more here: https://www.bizjournals.com/chicago/news/2020/03/25/startup-siwa-therapeutics-aims-to-find-a-cure-for.html